SLC5A2 and Hyperglycemia: Taken together, these data support SGLT2 inhibitors as a structural metabolic backbone for podocyte protection in hyperglycaemia, suitable for combination with pillar-directed modulators (e.g., autophagy, complement/inflammasome, cytoskeleton).